Symax Sl

Hyoscyamine Sulfate


Capellon Pharmaceuticals, Llc
Human Prescription Drug
NDC 64543-111
Symax Sl also known as Hyoscyamine Sulfate is a human prescription drug labeled by 'Capellon Pharmaceuticals, Llc'. National Drug Code (NDC) number for Symax Sl is 64543-111. This drug is available in dosage form of Tablet, Orally Disintegrating. The names of the active, medicinal ingredients in Symax Sl drug includes Hyoscyamine Sulfate - .125 mg/1 . The currest status of Symax Sl drug is Active.

Drug Information:

Drug NDC: 64543-111
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Symax Sl
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Hyoscyamine Sulfate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Capellon Pharmaceuticals, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet, Orally Disintegrating
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:HYOSCYAMINE SULFATE - .125 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Sep, 1996
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 19 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Capellon Pharmaceuticals, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1046982
1046984
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0364543111013
UPC stands for Universal Product Code.
UNII:F2R8V82B84
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
64543-111-01100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (64543-111-01)01 Sep, 1996N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Symax sl hyoscyamine sulfate d&c yellow no. 10 fd&c blue no. 1 lactose monohydrate magnesium stearate mannitol starch, corn stearic acid hyoscyamine sulfate hyoscyamine sl;125

Drug Interactions:

Drug interactions: absorption of other oral medications may be decreased during concurrent use with anticholinergics due to decreased gastrointestinal motility and delayed gastric emptying. drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.

Indications and Usage:

Indications and usage this product may be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries and diverticulitis. it can also be used to control gastric secretion, visceral spasm and hypermotility in cystitis, pylorospasm and associated abdominal cramps. along with appropriate analgesics, this product is indicated in symptomatic relief of biliary and renal colic and as a drying agent in the relief of symptoms of acute rhinitis. this product is effective as adjunctive therapy in the treatment of peptic ulcer and irritable bowel syndrome, acute enterocolitis and other functional gastrointestinal disorders.

Warnings:

Warnings heat prostration can occur with drug use in the event of high environmental temperature. diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy; in this instance, treatment would be inappropriate and possibly harmful. this product may cause drowsiness or blurred vision. patients taking this product should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous tasks while taking this drug.

General Precautions:

General: use caution in patients with hiatal hernia associated with reflex esophagitis. use extreme caution and only when needed in patients with autonomic neuropathy, hyperthyroidism, coronary heart disease, congestive heart failure and cardiac arrhythmia. investigate any tachycardia before giving any anticholinergic drugs since they may increase the heart rate. prolonged use of anticholinergics may decrease or inhibit salivary flow, thus contributing to the development of caries, periodontal disease, oral candidiasis, and discomfort.

Dosage and Administration:

Dosage and administration dosage may be adjusted according to the condition and severity of symptoms. may be taken with or without water. adults and adolescents 12 years and older: oral or sublingual, 1 to 2 tablets three or four times a day, thirty minutes to one hour before meals and at bedtime. dosage may be increased to every four hours as needed. do not exceed 12 tablets in 24 hours. note: geriatric patients may be more sensitive to the effects of the usual adult dose.

Contraindications:

Contraindications glaucoma, obstructive uropathy, obstructive diseases of the gastrointestinal tract, paralytic ileum, intestinal atony of elderly or debilitated patients, unstable cardiovascular status, severe ulcerative colitis, toxic megacolon, myasthenia gravis, and myocardial ischemia. this product is not recommended for use in children under twelve years of age.

Adverse Reactions:

Adverse reactions not all of the following adverse reactions have been reported with hyoscyamine sulfate. the following adverse reactions have been reported for pharmacologically similar drugs with anticholinergic- antispasmodic action. adverse reactions may include dryness of the mouth, urinary hesitancy and retention; blurred vision; tachycardia; palpitations; mydriasis; cycloplegia; increased ocular tension; loss of taste; headache; nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; allergic reactions or drug idiosyncrasies; urticaria and other dermal manifestations; ataxia; speech disturbance; some degree of mental confusion and/or excitement (especially in elderly persons); and decreased sweating.

Drug Interactions:

Drug interactions: absorption of other oral medications may be decreased during concurrent use with anticholinergics due to decreased gastrointestinal motility and delayed gastric emptying. drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.

Use in Pregnancy:

Pregnancy: pregnancy category c. animal reproduction studies have not been conducted with this product. it is also not known whether this product can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. hyoscyamine crosses the placenta. this product should be given to a pregnant woman only if clearly needed.

Pediatric Use:

Pediatric use: this product is not recommended for use in children under twelve years of age. infants and young children are especially susceptible to the toxic effects of anticholinergics. close supervision is recommended for infants and children with spastic paralysis or brain damage since an increased response to anticholinergics has been reported in these patients and dosage adjustments are often required. when anticholinergics are given to children where the environmental temperature is high, there is a risk of a rapid increase in body temperature because of these medications’ suppression of sweat gland activity. a paradoxical reaction characterized by hyperexcitability may occur in children taking large doses of anticholinergics.

Geriatric Use:

Geriatric use: geriatric patients may respond to usual doses of anticholinergics with excitement, agitation, drowsiness, or confusion. geriatric patients are especially susceptible to the anticholinergic side effects, such as constipation, dryness of mouth, and urinary retention (especially in males). if these side effects occur and continue or are severe, medication should probably be discontinued. caution is also recommended when anticholinergics are given to geriatric patients, because of the danger of precipitating undiagnosed glaucoma. memory may become severely impaired in geriatric patients, especially those who already have memory problems, with the continued use of anticholinergics since these drugs block the actions of acetylcholine, which is responsible for many functions of the brain, including memory functions.

Overdosage:

Overdosage the signs and symptoms of overdose are headache, nausea, vomiting, blurred vision, dilated pupils, hot dry skin, dizziness, dryness of the mouth, difficulty in swallowing and cns stimulation. measures to be taken are immediate lavage of the stomach and injection of physostigmine 0.5 to 2 mg intravenously and repeated as necessary up to a total of 5 mg. fever may be treated symptomatically (tepid water sponge baths, hypothermic blanket). excitement to a degree which demands attention may be managed with sodium thiopental 2% solution given slowly intravenously or chloral hydrate (100-200 ml of a 2% solution) by rectal infusion. in the event of progression of the curare-like effect to paralysis of the respiratory muscles, artificial respiration should be instituted and maintained until effective respiratory action returns. in rats, the ld 50 for hyoscyamine is 375 mg/kg. hyoscyamine is dialyzable.

Description:

Description each tablet for oral administration contains: hyoscyamine sulfate . . . 0.125 mg hyoscyamine sulfate is one of the principal anticholinergic/antispasmodic components of belladonna alkaloids. hyoscyamine sulfate is benzeneacetic acid, α-(hydroxymethyl)-, 8- methyl-8-azabicyclo[3.2.1]oct-3-yl ester, [3(s)- endo ]-, sulfate (2:1), dihydrate. (c 17 h 23 no 3 ) 2 • h 2 so 4 • 2h 2 o m.w. 712.85 hyoscyamine sulfate

Clinical Pharmacology:

Clinical pharmacology hyoscyamine has actions similar to those of atropine, but is more potent in both its central and peripheral effects. this product inhibits gastrointestinal propulsive motility and decreases gastric acid secretions. this product controls excessive pharyngeal, tracheal, and bronchial secretion. this product is absorbed totally and completely by sublingual administration as well as oral administration. once absorbed, this product disperses rapidly in the blood and is distributed throughout the entire body. the majority of hyoscyamine sulfate is excreted in the urine unchanged within the first 12 hours and only traces of hyoscyamine sulfate are found in the breast milk.

How Supplied:

How supplied symax ® -sl is supplied as green, round, sublingual, peppermint flavored tablets debossed "sl" over "125". available in bottles of 100 tablets, ndc 64543-111-01. storage and handling dispense in a tight, light-resistant container as defined in usp/nf, with a child-resistant closure. store at controlled room temperature between 20°-25°c (68°- 77°f), see usp controlled room temperature. keep this and all medication out of the reach of children. in case of accidental overdose, seek professional assistance or contact a poison control center immediately. manufactured for: capellon pharmaceuticals, llc ft. worth, tx 76118 rx only rev. 06/2014 500010-02

Information for Patients:

Information for patients: this medication should be taken 30 minutes to one hour before meals. this medication should be used with caution during exercise or hot weather; overheating may result in heat stroke. hyoscyamine may cause drowsiness, dizziness or blurred vision; patients should observe caution before driving, using machinery or performing other tasks requiring mental alertness.

Package Label Principal Display Panel:

Principal display panel figure-02


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.